Ratings FibroGen, Inc.

Equities

FGEN

US31572Q8087

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
1.22 ^USD	+7.96%		+7.96%	+37.65%

May. 07	Top Premarket Gainers	MT
May. 06	Transcript : FibroGen, Inc., Q1 2024 Earnings Call, May 06, 2024

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Most analysts recommend that the stock should be sold or reduced.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
FIBROGEN, INC.	+37.65%	121M	B-
MODERNA, INC.	+23.37%	47.02B	B-
LONZA GROUP AG	+50.13%	41.86B	A
IQVIA HOLDINGS INC.	-0.94%	41.76B	B
CELLTRION, INC.	-4.32%	28.8B	C
ICON PUBLIC LIMITED COMPANY	+11.29%	26.05B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.92%	19.15B	B
BIO-TECHNE CORPORATION	+3.20%	12.55B	B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.67%	11.82B	C+
MEDPACE HOLDINGS, INC.	+30.23%	12.34B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes